BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hengel RL, Ritter TE, Nathan RV, Van Anglen LJ, Schroeder CP, Dillon RJ, Marcella SW, Garey KW. Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study. Open Forum Infect Dis 2020;7:ofaa097. [PMID: 32363211 DOI: 10.1093/ofid/ofaa097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Johnson TM, Howard AH, Miller MA, Allen LL, Huang M, Molina KC, Bajrovic V. Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients. Open Forum Infect Dis 2021;8:ofab294. [PMID: 34262988 DOI: 10.1093/ofid/ofab294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021:ciab549. [PMID: 34164674 DOI: 10.1093/cid/ciab549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sehgal K, Khanna S. Immune response against Clostridioides difficile and translation to therapy. Therap Adv Gastroenterol 2021;14:17562848211014817. [PMID: 33995585 DOI: 10.1177/17562848211014817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021;73:755-7. [PMID: 34492699 DOI: 10.1093/cid/ciab718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. J Clin Med 2020;10:E2. [PMID: 33374989 DOI: 10.3390/jcm10010002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Reference Citation Analysis]
8 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Giacobbe DR, Dettori S, Di Bella S, Vena A, Granata G, Luzzati R, Petrosillo N, Bassetti M. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies. Infect Dis Ther 2020;9:481-94. [PMID: 32632582 DOI: 10.1007/s40121-020-00314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Khurana S, Kahl A, Yu K, DuPont AW. Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines. Fac Rev 2020;9:13. [PMID: 33659945 DOI: 10.12703/b/9-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Askar SF, Kenney RM, Tariq Z, Conner R, Williams J, Ramesh M, Alangaden GJ. Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients. J Pharm Pract 2022;:8971900221074929. [PMID: 35090351 DOI: 10.1177/08971900221074929] [Reference Citation Analysis]